Abstract: Objective To screen prognostic genes for neoadjuvant chemotherapy in patients with locally advanced breast cancer of luminal B type.Methods Ten locally advanced breast cancer patients of luminal B type were underwent DA regimen as neoadjuvant chemotherapy（docetaxel 75mg／m2iv， d1；epirubicin 80 mg／m2 iv， d1， 3 weeks as a cycle for 4 cycles）. Based on RECIST11 standard， 10 patients were divided into pathological complete remission（pCR） group（n=3） and non-pathological complete remission（npCR） group （n=7）. GeneChip human genome was used to screen prognostic genes for neoadjuvant chemotherapy in 10 luminal B breast cancer patients. Florescence quantitative PCR was conducted to confirm the different gene expression. Results Compared with npCR patients， 231 genes expression were up-regulated， 195 genes expression were downregulated in tumor samples of pCR patients；Compared with peri-tumor tissues， 357 genes expression were up-regulated and 544 genes expression were down-regulated in tumor samples of pCR patients. Compared with peri-tumor tissues， 143 genes expression were upregulated and 101 genes expression were down-regulated in the tumor samples of npCR patients. Compared with npCR patients, 98 genes expression were up-regulated and 67 genes expression were downregulated in peri-tumor samples of pCR patients. Statistically significant differences in gene expressions were noted in pCR group vs. npCR group， including 3 up-regulated genes of CYP4Z1， FGFL6 and BCAR4， as well as 3 down-regulated genes of FABP4， S100B and ALPH1L1. The expression of CYP4Z1 and BCAR4 in pCR patients was significantly lower than that of npCR patients（P＜0.05） confirmed by florescence quantitative PCR. Conclusion In patients with luminal B locally advanced breast cancer， lower expression of CYP4Z1 and BCAR4 may be associated with higher pCR rates in neoadjuvant chemotherapy receiving DA regimen.